Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
Supernus Pharmaceuticals continues its collaboration with actress Busy Philipps to raise awareness about ADHD in women and promote Qelbree®, a non-stimulant ADHD treatment. Philipps shares her personal experience with ADHD and how Qelbree has helped manage her symptoms. The campaign aims to empower women to advocate for their ADHD care, especially as ADHD Awareness Month approaches.
Qelbree is a once-daily non-stimulant medication approved for patients 6 years and older with ADHD. It's the first non-stimulant approved for adults with ADHD in 20 years. The drug has no evidence of abuse or misuse and can be refilled without needing a new prescription each month.
The press release includes important safety information, noting that Qelbree may increase suicidal thoughts and actions in some patients. It also mentions potential side effects and drug interactions.
Supernus Pharmaceuticals continua la sua collaborazione con l'attrice Busy Philipps per sensibilizzare sull'ADHD nelle donne e promuovere Qelbree®, un trattamento non stimolante per l'ADHD. Philipps condivide la sua esperienza personale con l'ADHD e come Qelbree l'abbia aiutata a gestire i suoi sintomi. La campagna mira a dare potere alle donne affinché possano difendere la propria assistenza per l'ADHD, soprattutto con l'arrivo del Mese di Sensibilizzazione sull'ADHD.
Qelbree è un farmaco non stimolante a dose giornaliera unica approvato per pazienti di età pari o superiore a 6 anni con ADHD. È il primo farmaco non stimolante approvato per gli adulti con ADHD negli ultimi 20 anni. Il farmaco non presenta prove di abuso o uso improprio e può essere rifatto senza necessità di una nuova prescrizione ogni mese.
Il comunicato stampa include informazioni di sicurezza importanti, notando che Qelbree può aumentare i pensieri e le azioni suicidarie in alcuni pazienti. Menziona anche effetti collaterali potenziali e interazioni farmacologiche.
Supernus Pharmaceuticals continúa su colaboración con la actriz Busy Philipps para crear conciencia sobre el TDAH en las mujeres y promover Qelbree®, un tratamiento para el TDAH que no es estimulante. Philipps comparte su experiencia personal con el TDAH y cómo Qelbree ha ayudado a manejar sus síntomas. La campaña tiene como objetivo empoderar a las mujeres para que aboguen por su atención del TDAH, especialmente con la proximidad del Mes de Concienciación sobre el TDAH.
Qelbree es un medicamento no estimulante de una vez al día aprobado para pacientes de 6 años en adelante con TDAH. Es el primer medicamento no estimulante aprobado para adultos con TDAH en 20 años. El medicamento no presenta evidencia de abuso o uso indebido y se puede volver a surtir sin necesidad de una nueva receta cada mes.
El comunicado de prensa incluye información importante sobre la seguridad, señalando que Qelbree puede aumentar los pensamientos y acciones suicidas en algunos pacientes. También menciona efectos secundarios potenciales e interacciones con otros medicamentos.
Supernus Pharmaceuticals는 여성을 위한 ADHD 인식 제고 및 비자극제 ADHD 치료제 Qelbree®의 홍보를 위해 배우 Busy Philipps와의 협력을 계속합니다. Philipps는 ADHD에 대한 개인적인 경험과 Qelbree가 증상 관리를 어떻게 도왔는지 공유합니다. 이 캠페인은 ADHD 인식의 달을 맞아 여성이 자신의 ADHD 치료를 advocate 할 수 있도록 힘을 주는 것을 목표로 하고 있습니다.
Qelbree는 6세 이상의 ADHD 환자를 위해 승인된 하루 한 번 복용하는 비자극제 약물입니다. 20년 만에 성인 ADHD에 대해 승인된 첫 번째 비자극제입니다. 이 약물은 남용이나 오용의 증거가 없으며 매달 새 처방전 없이도 재발급이 가능합니다.
보도자료에는 Qelbree가 일부 환자에서 자살 사고 및 행동을 증가시킬 수 있다는 중요한 안전 정보가 포함되어 있습니다. 또한 잠재적인 부작용 및 약물 상호작용에 대해서도 언급하고 있습니다.
Supernus Pharmaceuticals poursuit sa collaboration avec l'actrice Busy Philipps pour sensibiliser au THDA chez les femmes et promouvoir Qelbree®, un traitement non stimulant pour le THDA. Philipps partage son expérience personnelle avec le THDA et comment Qelbree l'a aidée à gérer ses symptômes. La campagne vise à donner aux femmes les moyens de défendre leurs soins concernant le THDA, surtout avec l'approche du Mois de Sensibilisation au THDA.
Qelbree est un médicament non stimulant à prise quotidienne approuvé pour les patients âgés de 6 ans et plus ayant un THDA. C'est le premier médicament non stimulant approuvé pour les adultes atteints de THDA depuis 20 ans. Le médicament ne présente aucune preuve d'abus ou de mauvaise utilisation et peut être renouvelé sans nécessiter d'ordonnance chaque mois.
Le communiqué de presse contient des informations de sécurité importantes, notant que Qelbree peut augmenter les pensées et actions suicidaires chez certains patients. Il mentionne également des effets secondaires potentiels et des interactions médicamenteuses.
Supernus Pharmaceuticals setzt seine Zusammenarbeit mit Schauspielerin Busy Philipps fort, um auf ADHS bei Frauen aufmerksam zu machen und Qelbree®, eine nicht stimulierende ADHS-Behandlung, zu fördern. Philipps teilt ihre persönlichen Erfahrungen mit ADHS und wie Qelbree ihr geholfen hat, ihre Symptome zu verwalten. Die Kampagne zielt darauf ab, Frauen zu empowern, sich für ihre ADHS-Behandlung einzusetzen, insbesondere mit dem bevorstehenden Monat des ADHS-Bewusstseins.
Qelbree ist ein einmal täglich einzunehmendes nicht stimulierendes Medikament, das für Patienten ab 6 Jahren mit ADHS zugelassen ist. Es ist das erste nicht stimulierende Medikament, das seit 20 Jahren für Erwachsene mit ADHS zugelassen wurde. Das Medikament zeigt keine Anzeichen von Missbrauch oder Fehlgebrauch und kann ohne monatlich neue Verschreibung wiederholt werden.
Die Pressemitteilung enthält wichtige Sicherheitsinformationen und weist darauf hin, dass Qelbree bei einigen Patienten suizidale Gedanken und Handlungen erhöhen kann. Sie erwähnt auch mögliche Nebenwirkungen und Arzneimittelwechselwirkungen.
- Collaboration with celebrity Busy Philipps to raise ADHD awareness, potentially increasing brand visibility
- Qelbree is the first non-stimulant ADHD treatment approved for adults in 20 years
- Qelbree has no evidence of abuse or misuse, potentially making it a preferred choice for some patients
- Convenient once-daily dosing and easy prescription refills for Qelbree
- Qelbree may increase suicidal thoughts and actions in some patients
- Potential side effects include increased blood pressure and heart rate
- Possible interactions with other medications, limiting its use for some patients
- Ahead of ADHD Awareness Month, Busy is sharing her ADHD diagnosis and Qelbree® (viloxazine extended-release capsules) treatment story to empower women living with ADHD to advocate for their care.
- ADHD often presents differently in women than in men, which can make it more challenging to recognize in women and ultimately leaving them undiagnosed and untreated.1
ROCKVILLE, Md., Sept. 24, 2024 (GLOBE NEWSWIRE) -- In a continued collaboration with Supernus Pharmaceuticals, actress, author, podcaster, late-night host, and mom, Busy Philipps, is speaking up this fall about her ongoing journey with attention-deficit/hyperactivity disorder (ADHD), bringing awareness to the often-overlooked symptoms of the condition in women and Qelbree, a non-stimulant ADHD treatment that has benefitted her.
With summer over and the school year now in full swing, the fall season brings for many adults a return to normal routines or schedules, as well as an opportunity for a fresh start. Busy knows first-hand just how difficult getting ‘back to schedule’ can be for the approximately 10 million adults living with ADHD, who may be experiencing symptoms of inattention, hyperactivity/impulsivity, or both.2 She’s sharing her story to help empower people, and especially women, living with ADHD to take action for a fresh start this fall and talk to their doctors about treatment options to help manage their condition.
“For many years living with unmanaged ADHD, I’d often start a task and never remember to finish, frequently feeling restless and unable to stay still. I would ramble on, get easily distracted and have trouble multitasking, and with my busy lifestyle, it was a challenge,” says Busy. “Now that I’m taking Qelbree, I’m relieved that my ADHD symptoms are more manageable. I only wish I’d taken charge of my ADHD sooner. That’s why I’m sharing my story to raise awareness about ADHD and help others who may be struggling with their diagnosis find a treatment option that works for them like Qelbree has worked for me.”
Qelbree is a novel, once-a-day, non-stimulant approach for patients 6 years and older with ADHD, and the first non-stimulant approved for adults with ADHD in 20 years. As a non-stimulant, Qelbree has no evidence of abuse or misuse and can be conveniently refilled without needing a new prescription each month.
“As a leader in treating ADHD, Supernus is committed to providing treatment options and education to help people living with ADHD like Busy Philipps manage their ADHD symptoms,” says Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “We appreciate Busy’s continued support and willingness to share her ADHD story and experience with Qelbree, especially leading into ADHD Awareness Month.”
For more information about Qelbree, visit Qelbree.com. Patients should speak to a doctor about all the medications they take, and to see if Qelbree could be right for them.
INDICATION
Qelbree® (viloxazine extended-release capsules) is a prescription medicine used to treat ADHD in adults and children 6 years and older.
IMPORTANT SAFETY INFORMATION
Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment or when the dose is changed. Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child’s moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.
You or your child should not take Qelbree if you or your child:
Take a medicine for depression called a monoamine oxidase inhibitor (MAOI) or have stopped taking an MAOI in the past 14 days. Also, you or your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline.
Qelbree can increase blood pressure and heart rate. Your or your child’s doctor will monitor these vital signs.
Qelbree may cause manic episodes in patients with bipolar disorder. Tell your doctor if you or your child show any signs of mania.
Do not drive or operate heavy machinery until you know how Qelbree will affect you or your child. Qelbree may cause you or your child to feel sleepy or tired.
The most common side effects of Qelbree in patients 6 to 17 years are sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability, and in adults, insomnia, headache, sleepiness, tiredness, nausea, decreased appetite, dry mouth, and constipation. These are not all the possible side effects of Qelbree.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see full Prescribing Information, including Boxed Warning, for Qelbree here.
1Holthe, M. E. G., Langvik, E. (2017). The Strives, Struggles, and Successes of Women Diagnosed with ADHD as Adults. SAGE Journals.
2Culpepper, L., Mattingly, G. (2010). Challenges in Identifying and Managing Attention-Deficit/Hyperactivity Disorder in Adults in the Primary Care Setting: A Review of the Literature. Primary Care Companion Journal of Clinical Psychiatry.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, and dyskinesia in PD patients receiving levodopa-based therapy. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Or
INVESTOR CONTACT:
Peter Vozzo
ICR Westwicke
Office: (443) 213-0505
Email: Peter.Vozzo@westwicke.com
MEDIA CONTACT:
Matthew Frappier
Tel: (646) 358-9683
Email: Matthew.Frappier@bcw-global.com
FAQ
What is Qelbree and how is it used to treat ADHD?
Why is Busy Philipps collaborating with Supernus Pharmaceuticals for ADHD awareness?
What are the main safety concerns associated with Qelbree (SUPN)?
How does Qelbree (SUPN) differ from stimulant ADHD medications?
